130 related articles for article (PubMed ID: 24026661)
1. High level of p37δ-mRNA relative to p110δ-mRNA in neuroblastoma tumors correlates with poor patient survival.
Fransson S; Ejeskär K
Med Oncol; 2013 Dec; 30(4):724. PubMed ID: 24026661
[TBL] [Abstract][Full Text] [Related]
2. p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors.
Fransson S; Uv A; Eriksson H; Andersson MK; Wettergren Y; Bergo M; Ejeskär K
Oncogene; 2012 Jul; 31(27):3277-86. PubMed ID: 22020336
[TBL] [Abstract][Full Text] [Related]
3. The Unique Non-Catalytic C-Terminus of P37delta-PI3K Adds Proliferative Properties In Vitro and In Vivo.
Ejeskär K; Vickes O; Kuchipudi A; Wettergren Y; Uv A; Rotter Sopasakis V
PLoS One; 2015; 10(5):e0127497. PubMed ID: 26024481
[TBL] [Abstract][Full Text] [Related]
4. Stage-dependent expression of PI3K/Akt‑pathway genes in neuroblastoma.
Fransson S; Abel F; Kogner P; Martinsson T; Ejeskär K
Int J Oncol; 2013 Feb; 42(2):609-16. PubMed ID: 23232578
[TBL] [Abstract][Full Text] [Related]
5. Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas.
Fransson S; Kogner P; Martinsson T; Ejeskär K
J Mol Signal; 2013 Apr; 8(1):4. PubMed ID: 23597230
[TBL] [Abstract][Full Text] [Related]
6. Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.
Boller D; Schramm A; Doepfner KT; Shalaby T; von Bueren AO; Eggert A; Grotzer MA; Arcaro A
Clin Cancer Res; 2008 Feb; 14(4):1172-81. PubMed ID: 18281552
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
8. FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma.
Santo EE; Stroeken P; Sluis PV; Koster J; Versteeg R; Westerhout EM
Cancer Res; 2013 Apr; 73(7):2189-98. PubMed ID: 23378341
[TBL] [Abstract][Full Text] [Related]
9. PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma.
Mohlin S; Hamidian A; von Stedingk K; Bridges E; Wigerup C; Bexell D; Påhlman S
Cancer Res; 2015 Nov; 75(21):4617-28. PubMed ID: 26432405
[TBL] [Abstract][Full Text] [Related]
10. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
[TBL] [Abstract][Full Text] [Related]
11. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
Iyengar S; Clear A; Bödör C; Maharaj L; Lee A; Calaminici M; Matthews J; Iqbal S; Auer R; Gribben J; Joel S
Blood; 2013 Mar; 121(12):2274-84. PubMed ID: 23341541
[TBL] [Abstract][Full Text] [Related]
12. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
13. Mutations in PIK3CA are infrequent in neuroblastoma.
Dam V; Morgan BT; Mazanek P; Hogarty MD
BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308
[TBL] [Abstract][Full Text] [Related]
14. PI3K/Akt signaling pathway triggers P2X7 receptor expression as a pro-survival factor of neuroblastoma cells under limiting growth conditions.
Gómez-Villafuertes R; García-Huerta P; Díaz-Hernández JI; Miras-Portugal MT
Sci Rep; 2015 Dec; 5():18417. PubMed ID: 26687764
[TBL] [Abstract][Full Text] [Related]
15. PIK3CD induces cell growth and invasion by activating AKT/GSK-3β/β-catenin signaling in colorectal cancer.
Chen JS; Huang JQ; Luo B; Dong SH; Wang RC; Jiang ZK; Xie YK; Yi W; Wen GM; Zhong JF
Cancer Sci; 2019 Mar; 110(3):997-1011. PubMed ID: 30618098
[TBL] [Abstract][Full Text] [Related]
16. The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation.
Beer-Hammer S; Zebedin E; von Holleben M; Alferink J; Reis B; Dresing P; Degrandi D; Scheu S; Hirsch E; Sexl V; Pfeffer K; Nürnberg B; Piekorz RP
J Leukoc Biol; 2010 Jun; 87(6):1083-95. PubMed ID: 20200404
[TBL] [Abstract][Full Text] [Related]
17. The PI3K/AKT signaling pathway: Associations of miRNAs with dysregulated gene expression in colorectal cancer.
Slattery ML; Mullany LE; Sakoda LC; Wolff RK; Stevens JR; Samowitz WS; Herrick JS
Mol Carcinog; 2018 Feb; 57(2):243-261. PubMed ID: 29068474
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic signaling of class I PI3K isoforms.
Denley A; Kang S; Karst U; Vogt PK
Oncogene; 2008 Apr; 27(18):2561-74. PubMed ID: 17998941
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas.
Knobbe CB; Reifenberger G
Brain Pathol; 2003 Oct; 13(4):507-18. PubMed ID: 14655756
[TBL] [Abstract][Full Text] [Related]
20. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
